CRBN and plasma cell myeloma: Several clinical studies have correlated the higher expression of CRBN gene in myeloma cells with the superior treatment response of a lenalidomide-based regimen [13] and a pomalidomide-based regimen [14], as well as longer progression-free survival during thalidomide maintenance therapy [15].